Abstract
SiRNA is an efficient tool to suppress the specific gene. Nek2 is a member of the serine/threonine kinase family. We previously reported the tumor suppressing effects of locally administered Nek2 siRNA (direct intra-tumorous injection) in several cancer xenograft models. However, there is little information regarding to the pharmacokinetics of locally administered siRNA. This study sought to elucidate the transmission rate to blood and incidence of side effects after local administration of Nek2 siRNA in rat model. First, we mixed different amount of Nek2 siRNA with rat plasma (0, 1, 10, 100 and 500 μM) and performed Northern blot analysis. Nek2 siRNA was detected in rat plasma in a concentration dependent manner. Next, the transmission of Nek2 siRNA to blood was evaluated after subcutaneous administration. Nek2 siRNA and biocollagen complexes were formed (500μM, 100μl) and were injected in femoral area. The blood was collected at different time point (5, 15, 30 and 60 min) and was analyzed by Northern blot. The detection of Nek2 siRNA in the blood was the highest at 15 min, and it disappeared within 1 h after the administration. There was no complication related to the local administration of Nek2 siRNA. Our data suggest that the local administration of siRNA is a safe delivery procedure with little cytotoxicity. However, further investigation will be needed for the future clinical application of siRNA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
